Melissa Stephenson, Author at BioTuesdays

Developments

CymaBay in $100-million non-dilutive financing for Phase 3 trial

CymaBay Therapeutics (NASDAQ:CBAY) announced a $100-million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the...

August 2, 2021

Developments

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...

July 28, 2021

Developments

FDA clears Asensus Surgical 510(k) for articulating instruments

Asensus Surgical (NYSE American:ASXC) received FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System robotic technology platform. Articulating instruments offer better...

July 28, 2021

Developments

Cybin receives conditional listing approval from NYSE American

Cybin (NEO:CYBN; OTCQB:CLXPF) has received conditional listing approval from the NYSE American stock exchange, under the ticker symbol, CYBN. In a statement, Doug Drysdale, CEO of Cybin, said conditional listing...

July 22, 2021

Markets

Stifel starts GH Research at buy; PT $26

Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...

July 20, 2021

Developments

iBio posts positive preclinical immunization studies with next gen COVID-19 vaccine candidate

iBio (NYSE American:IBIO) announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid (N) protein of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell...

July 16, 2021

Developments

Cognetivity ICA test to be deployed in new NHS brain clinic in UK

Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF) Integrated Cognitive Assessment (ICA) test is to form an integral part of a new and highly innovative clinic in the UK’s National Health Service (NHS) dedicated to...

July 15, 2021

Developments

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Closely-held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. A...

July 14, 2021

Developments

Hepion posts positive Phase 2a NASH data in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that all primary endpoints were met in its Phase 2a AMBITION clinical trial in patients with non-alcoholic steatohepatitis (NASH). The Phase 2a trial was designed to...

July 13, 2021

Developments

iBio establishes oncology drug discovery pipeline with 3 new antibody programs

In a major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming protein expression system, iBio (NYSE American:IBIO) is adding three anti-cancer targets to its pipeline of...

July 9, 2021

Author - Melissa Stephenson

CymaBay in $100-million non-dilutive financing for Phase 3 trial

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

FDA clears Asensus Surgical 510(k) for articulating instruments

Cybin receives conditional listing approval from NYSE American

Stifel starts GH Research at buy; PT $26

iBio posts positive preclinical immunization studies with next gen COVID-19 vaccine candidate

Cognetivity ICA test to be deployed in new NHS brain clinic in UK

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Hepion posts positive Phase 2a NASH data in AMBITION trial

iBio establishes oncology drug discovery pipeline with 3 new antibody programs

General

More